Detalhe da pesquisa
1.
How I treat refractory CRS and ICANS after CAR T-cell therapy.
Blood
; 141(20): 2430-2442, 2023 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36989488
2.
Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma.
Blood
; 140(5): 491-503, 2022 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35476848
3.
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.
Blood
; 137(19): 2621-2633, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512407
4.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Blood
; 138(24): 2499-2513, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34166502
5.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Haematologica
; 108(1): 98-109, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833303
6.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Am J Hematol
; 98(11): 1699-1710, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584447
7.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(4): 387-405, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390769
8.
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma.
Haematologica
; 106(4): 978-986, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32327504
9.
Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy.
Psychooncology
; 30(8): 1294-1301, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739548
10.
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.
Br J Haematol
; 189(1): 97-105, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32068243
11.
Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies.
Stem Cells
; 36(1): 36-44, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29024301
12.
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations.
Am J Hematol
; 99(6): 1196-1200, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546371
13.
Cellular therapy: Great promise, but at what cost?
Mol Ther
; 31(1): 5-6, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455550
14.
Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
Blood
; 137(13): 1832-1835, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33156925
15.
Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma.
Mol Ther
; 30(1): 14-16, 2022 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34921770
16.
Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy.
Br J Haematol
; 187(2): e35-e38, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31410842
17.
Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells.
Am J Hematol
; 94(9): E245-E247, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31211433
18.
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.
Lancet Haematol
; 11(6): e459-e470, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38734026
19.
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Blood Adv
; 8(8): 1857-1868, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38181508
20.
Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated With Longer Survival Among Patients With Nodal Peripheral T Cell Lymphoma.
Transplant Cell Ther
; 2024 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38740140